A PHASE 1, OPEN-LABEL, 3-TREATMENT, 6-SEQUENCE, 3-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF PF-07321332/RITONAVIR AND RITONAVIR ON THE PHARMACOKINETICS OF DABIGATRAN IN HEALTHY PARTICIPANTS
Latest Information Update: 01 Apr 2024
At a glance
- Drugs Dabigatran etexilate (Primary) ; Nirmatrelvir+ritonavir (Primary) ; Ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors Pfizer
- 18 Jan 2022 Status changed from recruiting to completed.
- 18 Oct 2021 Planned End Date changed from 22 Nov 2021 to 14 Nov 2021.
- 18 Oct 2021 Planned primary completion date changed from 22 Nov 2021 to 14 Nov 2021.